About the Plasma Cell Myeloma Session
Plasma cell myeloma, also known as multiple myeloma, is a type of cancer that affects plasma cells in the bone marrow. These abnormal plasma cells multiply uncontrollably, crowding out healthy blood cells and weakening bones. Recent research in cancer therapy has shown promising developments in treating plasma cell myeloma. Immunotherapies, such as CAR-T cell therapy, are being investigated to target and destroy cancerous plasma cells more effectively. Additionally, advancements in precision medicine allow for personalized treatment approaches based on a patient's genetic makeup and disease characteristics. Researchers are also exploring novel drug combinations and targeted therapies to improve outcomes and reduce the side effects of treatment. These innovations offer hope for better management and ultimately, a cure for plasma cell myeloma.
Topics Covered in Plasma Cell Myeloma
Bone Marrow Assessment
Lytic Bone Disease
Cytogenetic Risk
Stem Cell Transplant
BCMA-Directed Therapy
Minimal Residual Disease
Related Scientific Sessions at CIOC 2027
Why Attend the Plasma Cell Myeloma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Plasma Cell Myeloma work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Plasma Cell Myeloma research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Plasma Cell Myeloma track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Plasma Cell Myeloma Conference 2027 — FAQs
What is the Plasma Cell Myeloma track at CIOC 2027?
The Plasma Cell Myeloma track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Plasma Cell Myeloma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Plasma Cell Myeloma sessions?
Cancer researchers and clinicians, educators and students with an interest in Plasma Cell Myeloma are all welcome — whether presenting or attending.
Can I present my research in the Plasma Cell Myeloma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Plasma Cell Myeloma sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Plasma Cell Myeloma track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.